Adrenoceptor Alpha 2A Polymorphism (ADRA2A)
Adrenoceptor alpha 2A (ADRA2A) is a member of Alpha-2-adrenergic receptors that have a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system. Alpha-2A ADR is coded by the ADRA2A gene. The alpha-2-adrenergic receptors inhibit adenylate cyclase and it major role is modulating function of major neurotransmitters like noradrenaline, serotonin and dopamine. The single nucleotide polymorphism in ADRA2A, -1291 C>G (rs1800544), has been associated with severity of attention-deficit/hyperactivity disorder (ADHD) and disease management. Therefore, ADRA2A variant -1291 C>G is associated with a favorable response to methylphenidate in ADHD patients, inattentive type.
In addition, C1291G polymorphism of ADRA2A was found to modulate the clinical outcome of response to Dexmedetomidine, an alpha-2A ADR agonist that inhibits the release of noradrenaline in the central nervous system. Dexmedetomidine is a sedative and anesthetic agent used to assist in surgical procedures including coronary artery surgery. Patients with C1291G polymorphism (homozygous and heterozygous states) show increased levels of sedation compared to those who do not carry this polymorphism (non-carriers).
- Evaluation of methylphenidate therapy in patient with ADHD inattentive type
- To predict the levels of sedation to dexmedetomidine in patients undergoing coronary artery surgery
ADRA2A variant -1291 C>G is also associated with a favorable response to methylphenidate in ADHD patients, inattentive type.
Detection of C1291G polymorphism predicts higher levels of sedation to dexmedetomidine.
Absence of C1291G polymorphism doesn't exclude this effect since there might be other mutations in the ADRA2A that are not determined by this assay.
ADRA2A C-1291G C/C
Buccal swab and peripheral blood (EDTA) or saliva. Whole blood collected in lavender top tube (EDTA) or any anticoagulant collection devices.
Stability
- Ambient: 5 day
- Refrigerated: 7 days
- Biol Psychiatry. 2006 Nov 15;60(10):1028-33. [PMID: 16806103]
- Arch Gen Psychiatry. 2007 Feb;64(2):218-24. [PMID: 17283289]
- Mol Biol Rep. 2011;38:3383–3389 [PMID: 21104443]
- Prog Neuropsychopharmacol Biol Psychiatry. 2010 Feb 1;34(1):219-24. [PMID: 19922756]
- Science. 2010 Jan 8;327(5962):217-20 [PMID: 19965390]
- Clin Pharmacol Ther. 2006;79:173-85 [PMID: 16513442]